UK pharma firm Clinigen Group plc has opened an office in Tokyo and set up Clinigen KK, a move to strengthen its presence in Asia after the acquisition of Asia and Africa focused pharma firm Link Healthcare last year.
Announcing the launch of its business in Japan in a statement today, Clinigen said that alongside the launch, Clinigen KK will transfer the marketing authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from its Japanese distribution partner Nobel Pharma on November 1.
Last year, London-based Clinigen acquired Link Healthcare a specialist pharmaceutical and medical technology business focussed on the Asia, Africa and Australasia region for an initial consideration of $54.7 million (£44.5 million) and a maximum of approximately $122.9 million (£100 million) based on achievement of milestones.
Clinigen’s product Foscavir is a medicine indicated to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients. Japan was the first market where Clinigen successfully achieved a new license extension for HSCT patients in 2011.
“Japan remains an important market for Foscavir with more than 2,000 patients treated annually. Clinigen will assume full marketing and distribution responsibility for Foscavir from November, to supply the product to healthcare professionals and patients across Japan,” the company said.
“The opening of our Japanese business helps support our goals and will enable us to effectively serve the Japanese market by supplying our own products, beginning with Foscavir,” Clinigen CEO Shaun Chilton said.
At a time when many pharmaceutical and biotechnology companies are looking for specialist partners to work with them in Asia, the opening of the firm’s Japanese office gives it more opportunities to provide customers with its global expertise combined with local knowledge, he added.
Japan is the second largest pharmaceutical market globally and the Japanese business will allow the company to supply and distribute both licensed and unlicensed medicines in the country.